Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial

Jemma O'Connor, Michael J Vjecha, Andrew N Phillips, Brian Angus, David Cooper, Beatriz Grinsztejn, Gustavo Lopardo, Satyajit Das, Robin Wood, Aimee Wilkin, Hartwig Klinker, Pacharee Kantipong, Karin L Klingman, David Jilich, Elbushra Herieka, Eileen Denning, Ibrahim Abubakar, Fred Gordin, Jens D Lundgren, INSIGHT START study group, Jemma O'Connor, Michael J Vjecha, Andrew N Phillips, Brian Angus, David Cooper, Beatriz Grinsztejn, Gustavo Lopardo, Satyajit Das, Robin Wood, Aimee Wilkin, Hartwig Klinker, Pacharee Kantipong, Karin L Klingman, David Jilich, Elbushra Herieka, Eileen Denning, Ibrahim Abubakar, Fred Gordin, Jens D Lundgren, INSIGHT START study group

Abstract

Background: The effects of antiretroviral therapy on risk of severe bacterial infections in people with high CD4 cell counts have not been well described. In this study, we aimed to quantify the effects of immediate versus deferred ART on the risk of severe bacterial infection in people with high CD4 cell counts in a preplanned analysis of the START trial.

Methods: The START trial was a randomised controlled trial in ART-naive HIV-positive patients with CD4 cell count of more than 500 cells per μL assigned to immediate ART or deferral until their CD4 cell counts were lower than 350 cells per μL. We used Cox proportional hazards regression to model time to severe bacterial infection, which was defined as a composite endpoint of bacterial pneumonia (confirmed by the endpoint review committee), pulmonary or extrapulmonary tuberculosis, or any bacterial infectious disorder of grade 4 severity, that required unscheduled hospital admissions, or caused death. This study is registered with ClinicalTrials.gov, number NCT00867048.

Findings: Patients were recruited from April 15, 2009, to Dec 23, 2013. The data cutoff for follow-up was May 26, 2015. Of 4685 HIV-positive people enrolled, 120 had severe bacterial infections (immediate-initiation group n=34, deferred-initiation group n=86; median 2·8 years of follow-up). Immediate ART was associated with a reduced risk of severe bacterial infection compared with deferred ART (hazard ratio [HR] 0·39, 95% CI 0·26-0·57, p<0·0001). In the immediate-initiation group, average neutrophil count over follow-up was 321 cells per μL higher, and average CD4 cell count 194 cells per μL higher than the deferred-initiation group (p<0·0001). In univariable analysis, higher time-updated CD4 cell count (0·78, 0·71-0·85, p=0·0001) was associated with reduced risk of severe bacterial infection. Time-updated neutrophil count was not associated with severe bacterial infection. After adjustment for time-updated factors in multivariable analysis, particularly the CD4 cell count, the HR for immediate-initiation group moved closer to 1 (HR 0·84, 0·50-1·41, p=0·52). These results were consistent when subgroups of the severe bacterial infection composite were analysed separately.

Interpretation: Immediate ART reduces the risk of several severe bacterial infections in HIV-positive people with high CD4 cell count. This is partly explained by ART-induced increases in CD4 cell count, but not by increases in neutrophil count.

Funding: National Institute of Allergy and Infectious Diseases National Institutes of Health, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales, Bundesministerium für Bildung und Forschung, European AIDS Treatment Network, Australian National Health and Medical Research Council, UK National Institute for Health Research and Medical Research Council, Danish National Research Foundation.

Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. Published by Elsevier Ltd.. All rights reserved.

Figures

Figure 1
Figure 1
Change in laboratory markers during the study period Longitudinal mixed model adjusted for baseline value of biomarker and visit number. Estimated difference in CD4 count 194·2 cells per μL (95% CI 185·1–203·3; p3 (15·3–20·2; p<0·0001); albumin 0·09 g/dL (0·07–0·10; p<0·0001).
Figure 2
Figure 2
Factors associated with severe bacterial infection Number of events by treatment group for BMI: BMI lower than 18·5 kg/m2 (one immediate vs two deferred), BMI 18·5–24·9 kg/m2 (51 immediate vs 17 deferred), BMI 25·0–34·9 kg/m2 (20 immediate vs 11 deferred), and BMI 25·0 kg/m2 or higher (14 immediate vs 4 deferred). All models were stratified by a six-category variable describing the geographic region of residence (Africa, Asia, Australia, Europe and Israel, North America, South America and Mexico). Analyses of various subcategories of the composite endpoint are presented in the appendix (pp 2–9) and generated broadly consistent results. *Time-updated covariate. †Multivariable model also includes age (p=0·44), sex (p=0·07; trend towards women having lower risk than men), race or ethnicity (p=0·22), smoking status (p=0·09; trend towards smokers having higher risk than non-smokers), mode of HIV infection (p=0·88), time since diagnosis (p=0·89), hepatitis B (p=0·67), and hepatitis C status (p=0·43). ‡p value from likelihood ratio test.

References

    1. Lundgren D, Babiker AG, Gordin F. Initiation of antiretroviral therapy in early asymptomatic HIV Infection. N Engl J Med. 2015;373:795–807.
    1. British HIV Association British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy. 2015. (accessed Nov 3, 2015).
    1. European AIDS Clinical Society Guidelines version 8.0. October, 2015. (accessed Nov 3, 2015).
    1. WHO Guidelines on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. September, 2015. (accessed Nov 3, 2015).
    1. Anglaret X, Messou E, Ouassa T. Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Cote D'Ivoire. AIDS. 2003;17:575–584.
    1. Bjerk SM, Baker JV, Emery S. Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study. PLoS One. 2013;8:e56249.
    1. Corbett EL, Churchyard GJ, Charalambos S. Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis. 2002;34:1251–1258.
    1. Danel C, Moh R, Gabillard D. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373:808–822.
    1. Grosskurth H, Gray R, Hayes R, Mabey D, Wawer M. Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trials. Lancet. 2000;355:1981–1987.
    1. Severe P, Juste MAJ, Ambroise A. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;363:257–265.
    1. Elliott A, Schoenlaub L, Freches D, Mitchell W, Zhang GQ. Neutrophils play an important role in protective immunity against Coxiella burnetii infection. Infect Immun. 2015;83:3104–3113.
    1. Nauseef WM. How human neutrophils kill and degrade microbes: an integrated view. Immunol Rev. 2007;219:88–102.
    1. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol. 2006;6:173–182.
    1. Bennouna S, Bliss SK, Curiel TJ, Denkers EY. Cross-talk in the innate immune system: neutrophils instruct recruitment and activation of dendritic cells during microbial infection. J Immunol. 2003;171:6052–6058.
    1. Normark S, Normark BH, Hornef M. How neutrophils recognize bacteria and move toward infection. Nature Med. 2001;7:1182–1184.
    1. Babiker AG, Emery S, Fatkenheuer G. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials. 2013;10(suppl 1):S5–36.
    1. Almirall J, Bolibar I, Balanzo X, Gonzalez CA. Risk factors for community-acquired pneumonia in adults: a population-based case-control study. Eur Respir J. 1999;13:349–355.
    1. Baik I, Curhan GC, Rimm EB, Bendich A, Willett WC, Fawzi WW. A prospective study of age and lifestyle factors in relation to community-acquired pneumonia in US men and women. Arch Intern Med. 2000;160:3082–3088.
    1. Kornum J, Norgaard M, Dethlefsen C. Obesity and risk of subsequent hospitalisation with pneumonia. Eur Respir J. 2010;36:1330–1336.
    1. Blumentals WA, Nevitt A, Peng MM, Toovey S. Body mass index and the incidence of influenza-associated pneumonia in a UK primary care cohort. Influenza Other Respir Viruses. 2012;6:28–36.
    1. Inoue Y, Koizumi A, Wada Y. Risk and protective factors related to mortality from pneumonia among middleaged and elderly community residents: the JACC study. J Epidemiol. 2007;17:194–202.
    1. Phung D, Wang Z, Rutherford S, Huang C, Chu C. Body mass index and risk of pneumonia: a systematic review and meta-analysis. Obes Rev. 2013;14:839–857.
    1. Cohen MS, Chen YQ, McCauley M. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.
    1. Rodger AJ, Cambiano V, Bruun T. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016;316:171–181.
    1. Dye C. Global epidemiology of tuberculosis. Lancet. 2006;367:938–940.
    1. Corbett EL, Watt CJ, Walker N. The growing burden of tuberculosis—global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163:1009–1021.
    1. Kufa T, Mabuto T, Muchiri E. Incidence of HIV-associated tuberculosis among individuals taking combination antiretroviral therapy: a systematic review and meta-analysis. PLoS One. 2014;9:e111209.
    1. Toossi Z, Mayanja-Kizza H, Hirsch CS. Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients. Clin Exp Imm. 2001;123:233–238.
    1. Kohli R, Lo YT, Homel P. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study. Clin Infect Dis. 2006;43:90–98.
    1. Kenyon C, Buyze J, Colebunders R. Classification of incidence and prevalence of certain sexually transmitted infections by world regions. Int J Infect Dis. 2014;18:73–80.
    1. Ford N, Shubber Z, Meintjes G. Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. Lancet HIV. 2015;2:e438–e444.
    1. INSIGHT Criteria for event reporting in START. 2010. (accessed Dec 16, 2016).

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj